References
- Temple , R. J. 1995 . “ A regulatory authority's opinion about surrogate endpoints ” . In Clinical measurement in drug evaluation , Edited by: Nimmo , W. S. and Tucker , G. T. 3 – 22 . New York : John Wiley and Sons .
- Temple , R. J. 1999 . Are surrogate markers adequate to assess cardiovascular disease drugs? . Journal of the American Medical Association , 282 : 790 – 795 .
- U.S. Food and Drug Administration . 2000, May 19 . Female sexual dysfunction: Clinical development of drug products for treatment . Federal Register , 65 : 31916